Select Page

Ceftum injection

Dexa Medica

Product packaging may vary from one country to another.

Ingredients in every vial

Ceftazidime 1 g

Each package contains

1 vial of 1 g

Other details

Dosage form:Injection
Flavour None

W.H.O. classification

ATC Level 1 J - Antiinfectives for systemic use
ATC Level 2 J01 - Antibacterials for Systemic Use
ATC Level 3 J01D - Other Beta-Lactam Antibacterials in ATC



CONSULT YOUR DOCTORSafety of this item for use during pregnancy has not been established. Please consult your doctor.


CAUTIONThis item may not be safe for use during lactation. Use with caution and after consultation with your doctor.


CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.


CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.

Available in


Dosage information

25 to 60 mg/kg/day given as two divided doses has proved to be effective.

The usual dosage range for children aged over two months is 30 to 100 mg/kg/day, given as two or three divided doses.

Doses up to 150 mg/kg/day (maximum 6 g daily) in three divided doses may be given to infected immunocompromized or fibrocystic children or children with meningitis.

1 to 6 g daily, may be given each dosage of 500 mg, 1 g or 2 g given 12 or 8-hourly by IV or IM injection.

In urinary infections and in many less serious infections:
500 mg or 1 g 12-hourly is usually adequate.

In the majority of infections:
1 g 8-hourly or 2 g 12-hourly should be given

In very severe infections, especially in immunocompromized patients, including those with neutropenia:
2 g 8 or 12-hourly should be administered.

In fibrocystic adults with normal renal function who have pseudomonas lung infections:
high doses of 100 to 150 mg/kg/day as three divided doses should be used

In adults with normal renal function 9 g/day has been used safely.

Ceftazidime is used parenterally, the dosage depending upon the severity, sensitivity, type of infection, age, weight, and renal function of the patient.

Ceftazidime may be given intravenously or by deep intramuscular injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh.

In patients with impaired renal function it is recommended that the dosage of ceftazidime should be adjusted or reduced.

CrCl >50ml/minute:
usual dose every 8-12 hours.

CrCl 31-50 ml/minute:
1.0 g every 12 hours

CrCl 16-30 ml/minute:
1.0 g every 24 hours

CrCl 6-15 ml/minute:
0.5 g every 24 hours

CrCl <5 ml/minute: 0.5 g every 48 hours Hemodialysis: 1.0 g after hemodialysis Peritoneal dialysis: 0.5 every 24 hours


Ceftazidime is used for the treatment of serious infections caused by susceptible, organisms as follows:
– In general: septicemia, bacteremia, peritonitis, meningitis, infections in immunosuppressed patients with hematological or solid malignancies, and in patients in intensive care units with specific problems, for example infected burns.
– Lower respiratory tract infections: for example pneumonia, bronchopneumonia, infected pleurisy, empyema, lung abscess, infected bronchiectasis and in lung infections in patients with cystic fibrosis.
– Urinary tract infections: for example acute and chronic pyelonephritis, pyelitis, prostatitis, renal abscesses.
– Skin and soft tissue infections: for example erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis, skin ulcers.
– Biliary and abdominal infections: for example cholangitis, cholecystitis, empyema of gallbladder, intra-abdominal abscesses, peritonitis, diverticulitis, pelvic inflammatory diseases.
– Bone and joint infections: for example osteitis, osteomyelitis, septic arthritis, infected bursitis.
– Dialysis: infections associated with hemo and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (CAPD). Prior to initiation of ceftazidime therapy, appropriate specimens should be obtained for identification of the causative organism and in vitro susceptibility tests. Ceftazidime therapy may be started pending results of susceptibility tests, but should be discontinued if the organism is found to be resistant to the drug. When the causative organism is unknown, ceftazidime and concomitant therapy with other anti-infective agents may be indicated pending results of in vitro susceptibility tests. In severe or life-threatening infections or in immunocompromized patients, ceftazidime may be used concomitantly with other anti-infectives such as aminoglycosides, vancomycin, or clindamycin.
The drugs should generally be administered separately.